PAGE 1
WES MOORE, Governor Ch. 323

Chapter 323

(House Bill 1217)

AN ACT concerning

Maryland Medical Assistance Program and Health Insurance – Required
Coverage for Biomarker Testing

FOR the purpose of requiring the Maryland Medical Assistance Program and certain
insurers, nonprofit health service plans, health maintenance organizations, and
managed care organizations to provide coverage for biomarker testing that is
supported by medical and scientific evidence; establishing requirements for
deductibles, copayments, coinsurance, and utilization review for biomarker testing;
and generally relating to the coverage of biomarker testing by the Maryland Medical
Assistance Program and health insurance carriers.

BY adding to
Article – Health – General
Section 15–102.3(k) and 15–103(a)(2)(xxii)
Annotated Code of Maryland
(2019 Replacement Volume and 2022 Supplement)

BY repealing and reenacting, without amendments,
Article – Health – General
Section 15–103(a)(1)
Annotated Code of Maryland
(2019 Replacement Volume and 2022 Supplement)

BY repealing and reenacting, with amendments,
Article – Health – General
Section 15–103(a)(2)(xx) and (xxi)
Annotated Code of Maryland
(2019 Replacement Volume and 2022 Supplement)

BY adding to
Article – Insurance
Section 15–859
Annotated Code of Maryland
(2017 Replacement Volume and 2022 Supplement)

SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
That the Laws of Maryland read as follows:

Article – Health – General

15–102.3.
– 1 –

PAGE 2
Ch. 323 2023 LAWS OF MARYLAND

(K) ~~THE~~ BEGINNING JULY 1, 2025, § 15–859THE PROVISIONS OF OF THE
INSURANCE ARTICLE APPLY TO MANAGED CARE ORGANIZATIONS IN THE SAME
CARRIERS.MANNER THEY APPLY TO

15–103.

(a) (1) The Secretary shall administer the Maryland Medical Assistance
Program.

(2) The Program:

(xx) Beginning on July 1, 2023, shall provide, subject to federal
approval and limitations of the State budget, community violence prevention services in
[and]accordance with § 15–141.3 of this subtitle;

(xxi) Beginning on January 1, 2023, shall provide, subject to the
limitations of the State budget, and as permitted by federal law, coverage for self–measured
blood pressure monitoring for all Program recipients diagnosed with uncontrolled high
blood pressure, including:

1. The provision of validated home blood pressure monitors;
and

2. Reimbursement of health care provider and other staff
time used for patient training, transmission of blood pressure data, interpretation of blood
pressure readings and reporting, and the delivery of co–interventions, including
educational materials or classes, behavioral change management, and medication
management; AND

(XXII)BEGINNING ~~JANUARY~~ ~~1,~~ ~~2024~~ JULY 1, 2025,ON SHALL
PROVIDE, STATE BUDGET,SUBJECT TO THE LIMITATIONS OF THE AND AS
LAW,PERMITTED BY FEDERAL COVERAGE FOR BIOMARKER TESTING IN
§ 15–859 INSURANCE ARTICLE.ACCORDANCE WITH OF THE

Article – Insurance

15–859.

(A) (1) IN THIS SECTION THE FOLLOWING WORDS HAVE THE MEANINGS
INDICATED.

(2) (I) “BIOMARKER” MEANS A CHARACTERISTIC THAT IS
OBJECTIVELY MEASURED AND EVALUATED AS AN INDICATOR OF NORMAL
PROCESSES, PROCESSES,BIOLOGICAL PATHOGENIC OR PHARMACOLOGIC

– 2 –

PAGE 3
WES MOORE, Governor Ch. 323

INTERVENTION,RESPONSES TO A SPECIFIC THERAPEUTIC INCLUDING KNOWN
GENE–DRUG INTERACTIONS FOR MEDICATIONS BEING CONSIDERED FOR USE OR
ADMINISTERED.ALREADY BEING

(II) “BIOMARKER” MUTATIONS,INCLUDES GENE
GENES, EXPRESSION.CHARACTERISTICS OF OR PROTEIN

(3) (I) “BIOMARKER TESTING” PATIENT’SIS THE ANALYSIS OF A
TISSUE, BLOOD, BIOMARKER,OR OTHER BIOSPECIMEN FOR THE PRESENCE OF A
WHICH:THE RESULTS OF

1. PROVIDE INFORMATION THAT MAY BE USED IN THE
FORMULATION OF A TREATMENT OR MONITORING STRATEGY THAT INFORMS A
PATIENT’S DECISION;OUTCOME AND IMPACTS THE CLINICAL AND

2. INCLUDE BOTH INFORMATION THAT IS ACTIONABLE
AND SOME INFORMATION THAT CANNOT BE IMMEDIATELY USED IN THE
DECISION.FORMULATION OF A CLINICAL

(II) “BIOMARKER TESTING” SINGLE–ANALYTEINCLUDES
TESTS, MULTI–PLEX TESTS, EXPRESSION, EXOME,PANEL PROTEIN AND WHOLE
GENOME, SEQUENCING.WHOLE AND WHOLE TRANSCRIPTOME

(B) THIS TO:SECTION APPLIES

(1) INSURERS AND NONPROFIT HEALTH SERVICE PLANS THAT
HOSPITAL, MEDICAL,PROVIDE OR SURGICAL BENEFITS TO INDIVIDUALS OR GROUPS
EXPENSE–INCURREDON AN BASIS UNDER HEALTH INSURANCE POLICIES OR
STATE;CONTRACTS THAT ARE ISSUED OR DELIVERED IN THE AND

(2) HEALTH MAINTENANCE ORGANIZATIONS THAT PROVIDE
HOSPITAL, MEDICAL, OR SURGICAL BENEFITS TO INDIVIDUALS OR GROUPS UNDER
STATE.CONTRACTS THAT ARE ISSUED OR DELIVERED IN THE

(C) AN ENTITY SUBJECT TO THIS SECTION SHALL PROVIDE COVERAGE FOR
DIAGNOSIS, TREATMENT,BIOMARKER TESTING FOR THE PURPOSE OF APPROPRIATE
MANAGEMENT, OR ONGOING MONITORING OF A DISEASE OR CONDITION THAT IS
EVIDENCE, TESTING:SUPPORTED BY MEDICAL AND SCIENTIFIC INCLUDING

(1) U.S. FOOD DRUGCLEARED OR APPROVED BY THE AND
ADMINISTRATION;

– 3 –

PAGE 4
Ch. 323 2023 LAWS OF MARYLAND

(2) REQUIRED OR RECOMMENDED FOR A DRUG APPROVED BY THE
U.S. FOOD DRUG ADMINISTRATIONAND TO ENSURE AN INSURED OR ENROLLEE IS
TREATMENT;A GOOD CANDIDATE FOR THE DRUG

(3) REQUIRED OR RECOMMENDED THROUGH A WARNING OR
U.S. FOOD DRUGPRECAUTION FOR A DRUG APPROVED BY THE AND
ADMINISTRATION TO IDENTIFY WHETHER AN INSURED OR ENROLLEE WILL HAVE AN
DOSAGE;ADVERSE REACTION TO THE DRUG TREATMENT OR

(4) CENTERS MEDICARE MEDICAIDCOVERED UNDER A FOR AND
SERVICES NATIONAL COVERAGE DETERMINATION MEDICAREOR
ADMINISTRATIVE CONTRACTOR LOCAL COVERAGE DETERMINATION; OR

(5) SUPPORTED BY NATIONALLY RECOGNIZED CLINICAL PRACTICE
ARE:GUIDELINES THAT

(I) DEVELOPED BY INDEPENDENT ORGANIZATIONS OR
MEDICAL PROFESSIONAL SOCIETIES USING A TRANSPARENT METHODOLOGY AND
POLICY;REPORTING STRUCTURE AND THAT HAVE A CONFLICT OF INTEREST AND

(II) ESTABLISHED STANDARDS OF CARE INFORMED BY A
SYSTEMATIC REVIEW OF EVIDENCE AND AN ASSESSMENT OF THE BENEFITS AND
RISKS OF ALTERNATIVE CARE OPTIONS AND INCLUDE RECOMMENDATIONS
CARE;INTENDED TO OPTIMIZE PATIENT ~~OR~~

~~(6)~~ ~~ARE:~~~~SUPPORTED~~ ~~BY~~ ~~CONSENSUS~~ ~~STATEMENTS~~ ~~THAT~~

~~(I)~~ ~~INDEPENDENT,~~~~DEVELOPED~~ ~~BY~~ ~~AN~~ ~~MULTIDISCIPLINARY~~
~~PANEL~~ ~~OF~~ ~~EXPERTS~~ ~~USING~~ ~~A~~ ~~TRANSPARENT~~ ~~METHODOLOGY~~ ~~AND~~ ~~REPORTING~~
~~POLICY;~~~~STRUCTURE~~ ~~AND~~ ~~THAT~~ ~~HAVE~~ ~~A~~ ~~CONFLICT~~ ~~OF~~ ~~INTEREST~~ ~~AND~~

~~(II)~~ ~~AIMED~~ ~~AT~~ ~~SPECIFIC~~ ~~CLINICAL~~ ~~CIRCUMSTANCES~~ ~~AND~~ ~~BASE~~
~~THE~~ ~~STATEMENTS~~ ~~ON~~ ~~THE~~ ~~BEST~~ ~~AVAILABLE~~ ~~EVIDENCE~~ ~~FOR~~ ~~THE~~ ~~PURPOSE~~ ~~OF~~
~~CARE.~~~~OPTIMIZING~~ ~~THE~~ ~~OUTCOMES~~ ~~OF~~ ~~CLINICAL~~

(D) AN ENTITY SUBJECT TO THIS SECTION SHALL ENSURE THAT THE
(C)COVERAGE REQUIRED UNDER SUBSECTION OF THIS SECTION IS PROVIDED IN A
MANNER THAT LIMITS DISRUPTIONS IN CARE INCLUDING THE NEED FOR MULTIPLE
SAMPLES.BIOPSIES OR BIOSPECIMEN

(E) (1) SUBJECT (2) SUBSECTION,TO PARAGRAPH OF THIS THE
COVERAGE REQUIRED UNDER THIS SECTION MAY BE SUBJECT TO THE ANNUAL
DEDUCTIBLES, COPAYMENTS, OR COINSURANCE REQUIREMENTS IMPOSED BY AN

– 4 –

PAGE 5
WES MOORE, Governor Ch. 323

ENTITY SUBJECT TO THIS SECTION FOR SIMILAR COVERAGES UNDER THE SAME
CONTRACT.HEALTH INSURANCE POLICY OR

(2) THE DEDUCTIBLES, COPAYMENTS,ANNUAL OR COINSURANCE
(1)REQUIREMENTS IMPOSED UNDER PARAGRAPH OF THIS SUBSECTION FOR THE
COVERAGE REQUIRED UNDER THIS SECTION MAY NOT BE GREATER THAN THE
DEDUCTIBLES, COPAYMENTS,ANNUAL OR COINSURANCE REQUIREMENTS IMPOSED
COVERAGES.BY THE ENTITY FOR SIMILAR

~~(F)~~ ~~(1)~~ ~~AN~~ ~~ENTITY~~ ~~SUBJECT~~ ~~TO~~ ~~THIS~~ ~~SECTION~~ ~~THAT~~ ~~REQUIRES~~ ~~PRIOR~~
~~AUTHORIZATION~~ ~~OR~~ ~~A~~ ~~SIMILAR~~ ~~UTILIZATION~~ ~~REVIEW~~ ~~PROCEDURE~~ ~~FOR~~ ~~THE~~
~~(C)~~~~COVERAGE~~ ~~REQUIRED~~ ~~UNDER~~ ~~SUBSECTION~~ ~~OF~~ ~~THIS~~ ~~SECTION~~ ~~SHALL~~ ~~MAKE~~ ~~A~~
~~DETERMINATION~~ ~~REGARDING~~ ~~A~~ ~~REQUEST~~ ~~FOR~~ ~~APPROVAL~~ ~~WHEN~~ ~~SUBMITTED~~
~~ELECTRONICALLY:~~

~~(I)~~ ~~IN~~ ~~REAL~~ ~~TIME~~ ~~IF~~ ~~THE~~ ~~BIOMARKER~~ ~~TESTING~~ ~~IS~~ ~~TO~~ ~~GUIDE~~ ~~THE~~
~~PROVISION~~ ~~OF~~ ~~PHARMACEUTICAL~~ ~~SERVICES~~ ~~THAT~~ ~~ARE~~ ~~URGENT~~ ~~AND~~ ~~NO~~
~~REQUEST;~~~~ADDITIONAL~~ ~~INFORMATION~~ ~~IS~~ ~~NEEDED~~ ~~TO~~ ~~PROCESS~~ ~~THE~~ ~~AND~~

~~(II)~~ ~~FOR~~ ~~REQUESTS,~~ ~~§~~~~OTHER~~ ~~IN~~ ~~ACCORDANCE~~ ~~WITH~~
~~19–108.2~~ ~~HEALTH~~ ~~–~~ ~~GENERAL~~ ~~ARTICLE.~~~~OF~~ ~~THE~~

~~(2)~~ ~~IF~~ ~~A~~ ~~RESPONSE~~ ~~TO~~ ~~A~~ ~~PRIOR~~ ~~AUTHORIZATION~~ ~~OR~~ ~~SIMILAR~~
~~UTILIZATION~~ ~~REVIEW~~ ~~REQUEST~~ ~~FOR~~ ~~APPROVAL~~ ~~IS~~ ~~NOT~~ ~~RECEIVED~~ ~~IN~~ ~~THE~~ ~~TIME~~
~~SUBSECTION,~~~~FRAMES~~ ~~REQUIRED~~ ~~UNDER~~ ~~THIS~~ ~~THE~~ ~~REQUEST~~ ~~SHALL~~ ~~BE~~
~~APPROVED.~~~~CONSIDERED~~

SECTION 2. AND BE IT FURTHER ENACTED, That on or before December 1,
2024, the Maryland Department of Health shall report to the Governor and, in accordance
with § 2–1257 of the State Government Article, the General Assembly on the following:

(1) the fiscal impact of the ~~biomarkers~~ biomarker testing coverage required
under Section 1 of this Act on the Maryland Medical Assistance Program’s policy on
~~biomarkers~~ biomarker testing coverage for specific cancers during fiscal year 2024;

(2) any available data on use of ~~biomarkers~~ biomarker testing by race and
ethnicity in the Program;

(3) the anticipated fiscal and access impacts of expanding the coverage
required under Section 1 of this Act to the Maryland Medical Assistance Program in fiscal
year 2026; ~~and~~

(4) whether to establish a cap on the amount of reimbursement for
biomarker testing coverage and, if recommended:

– 5 –

PAGE 6
Ch. 323 2023 LAWS OF MARYLAND

(i) the recommended cap amount; and

(ii) the anticipated fiscal and access impacts of establishing the cap;
and

~~(4)~~ (5) recommendations on any legislative changes to the requirements
established under Section 1 of this Act relating to the Maryland Medical Assistance
Program, including managed care organizations.

SECTION 3. AND BE IT FURTHER ENACTED, That on or before December 1,
2025, the Maryland Health Care Commission shall report to the Senate Finance Committee
and the House Health and Government Operations Committee, in accordance with §
2–1257 of the State Government Article, on the impact of providing biomarker testing
coverage required under Section 1 of this Act, including an analysis of the impact of
providing access to biomarker testing to individuals based on race, gender, age, and public
or private insurance.

SECTION ~~2.~~ 4. AND BE IT FURTHER ENACTED, That Section 1 of this Act shall
apply to all policies, contracts, and health benefit plans issued, delivered, or renewed in the
State on or after January 1, 2024.

SECTION ~~3.~~ 5. AND BE IT FURTHER ENACTED, That this Act shall take effect
January 1, 2024.

Approved by the Governor, May 3, 2023.

– 6 –